Sugi Predict

Sugi Predict / Compounds / SCHEMBL3571702

SCHEMBL3571702

SCHEMBL3571702

COC(=O)c1cccc2ccc(Cl)cc12

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NR4A2 P43354 2/20 0.54
▸ ABL1 P00519 1/20 0.53
▸ SLC6A4 P31645 2/20 0.50
▸ SLC6A3 Q01959 2/20 0.50
▸ PLA2G2A P14555 3/20 0.49
▸ MTNR1A P48039 1/20 0.49
▸ CHEK1 O14757 1/20 0.48
▸ SLC6A2 P23975 1/20 0.48
▸ KDM4E B2RXH2 3/20 0.47
▸ MEN1 O00255 3/20 0.46
▸ MAPT P10636 3/20 0.46
▸ KMT2A Q03164 3/20 0.46
▸ NPSR1 Q6W5P4 2/20 0.46
▸ LMNA P02545 1/20 0.46
▸ HTT P42858 1/20 0.46
▸ RXFP1 Q9HBX9 1/20 0.46
▸ RAB9A P51151 1/20 0.45
▸ ALDH1A1 P00352 2/20 0.44
▸ HPGD P15428 2/20 0.44
▸ SMN1; SMN2 Q16637 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29792644 1.00 NR4A2 (0.54) NR4A2ABL1SLC6A4SLC6A3PLA2G2A
SCHEMBL9125331 0.87 NR4A2 (0.54) NR4A2ABL1SLC6A4SLC6A3PLA2G2A
SCHEMBL29374722 0.87 NR4A2 (0.54) NR4A2ABL1SLC6A4SLC6A3PLA2G2A
SCHEMBL4960197 0.87 KMT2A (0.44) NR4A2MTNR1AKDM4EMEN1MAPT
SCHEMBL19733167 0.83 ALDH1A1 (0.56) SLC6A4SLC6A3MTNR1ASLC6A2KDM4E
SCHEMBL29576093 0.82 MAPT (0.51) SLC6A4SLC6A3MTNR1ASLC6A2KDM4E
SCHEMBL21845580 0.82 NR4A2 (0.53) NR4A2SLC6A4SLC6A3MTNR1ASLC6A2
SCHEMBL2114008 0.82 CA12 (0.54) SLC6A4SLC6A3MTNR1ASLC6A2KDM4E
SCHEMBL68296 0.82 MAPT (0.51) SLC6A4SLC6A3MTNR1ASLC6A2KDM4E
SCHEMBL4117942 0.81 CA12 (0.47) NR4A2MTNR1AKDM4EMEN1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12221441-B2 Plasma kallikrein inhibitors and uses thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2025-02-11 — — US disclosed
EP-4477220-A2 PLASMA KALLIKREIN INHIBITORS AND USES THEREOF Takeda Pharmaceutical Company Limited (JP) 2024-12-18 — — EP disclosed
EP-4031547-B1 PLASMA KALLIKREIN INHIBITORS AND USES THEREOF TAKEDA PHARMACEUTICALS CO (JP) 2024-07-17 — — EP disclosed
US-20230391773-A1 PLASMA KALLIKREIN INHIBITORS AND USES THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2023-12-07 — — US disclosed
US-11787796-B2 Plasma Kallikrein inhibitors and uses thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2023-10-17 — — US disclosed
US-11787796-B2 Plasma Kallikrein inhibitors and uses thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2023-10-17 — — US disclosed
US-11787796-B2 Plasma Kallikrein inhibitors and uses thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2023-10-17 — — US disclosed
EP-4031547-A1 PLASMA KALLIKREIN INHIBITORS AND USES THEREOF Takeda Pharmaceutical Company Limited (JP) 2022-07-27 — — EP disclosed
CN-114728962-A Plasma kallikrein inhibitors and uses thereof 武田药品工业有限公司 2022-07-08 — — CN disclosed
WO-2021055621-A1 PLASMA KALLIKREIN INHIBITORS AND USES THEREOF SHIRE HUMAN GENETIC THERAPIES, INC. (US) 2021-03-25 — — WO disclosed
US-20210078999-A1 PLASMA KALLIKREIN INHIBITORS AND USES THEREOF CHARLES RIVER LABORATORIES, INC. 2021-03-18 — — US disclosed
US-20210078999-A1 PLASMA KALLIKREIN INHIBITORS AND USES THEREOF CHARLES RIVER LABORATORIES, INC. 2021-03-18 — — US disclosed
US-20130028843-A1 KALLIKREIN 7 MODULATORS NOVARTIS AG (CH) 2013-01-31 — — US disclosed
US-8309596-B2 Kallikrein 7 modulators NOVARTIS AG (CH) 2012-11-13 — — US disclosed
US-20100256144-A1 Kallikrein 7 modulators NOVARTIS AG (CH) 2010-10-07 — — US disclosed
EP-2170939-A1 KALLIKREIN 7 MODULATORS Novartis Ag (CH) 2010-04-07 — — EP disclosed
WO-2009000878-A1 KALLIKREIN 7 MODULATORS NOVARTIS AG (CH) 2008-12-31 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130028843-A1 KALLIKREIN 7 MODULATORS KLK7, KLK5, KLKB1 NR4A2 4664/4885ABL1 2795/4885SLC6A4 3082/4885
US-12221441-B2 Plasma kallikrein inhibitors and uses thereof KLKB1, KLK1, KLK5 NR4A2 4467/4885ABL1 1546/4885SLC6A4 3747/4885
US-11787796-B2 Plasma Kallikrein inhibitors and uses thereof KLKB1, KLK1, KLK5 NR4A2 4467/4885ABL1 1546/4885SLC6A4 3747/4885
US-20100256144-A1 Kallikrein 7 modulators KLK7, KLK5, KLKB1 NR4A2 4664/4885ABL1 2795/4885SLC6A4 3082/4885
US-20230391773-A1 PLASMA KALLIKREIN INHIBITORS AND USES THEREOF KLKB1, KLK1, KLK5 NR4A2 4467/4885ABL1 1546/4885SLC6A4 3747/4885
US-20210078999-A1 PLASMA KALLIKREIN INHIBITORS AND USES THEREOF KLKB1, KLK1, KLK5 NR4A2 4467/4885ABL1 1546/4885SLC6A4 3747/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.